◀ Back to MAP2K1
MAP2K1 — PIK3CA
Pathways - manually collected, often from reviews:
-
KEGG Glioma:
MAP2K1/MAP2K2
→
MAPK1/MAPK3/PIK3CA/PIK3CB/PIK3CD/PIK3CG
(protein-protein, activation)
Text-mined interactions from Literome
Lin et al., J Biol Chem 2003
:
Phosphatidylinositol 3-kinase , protein kinase C, and
MEK1/2 kinase
regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites
Gingery et al., J Cell Biochem 2003
(MAP Kinase Signaling System) :
PI3K inhibition also
blocked MEK1/2 , ERK1/2, and AKT phosphorylation and NFkappaB activation in purified osteoclasts
Levinthal et al., J Biol Chem 2004
:
Furthermore, we show that transient
PI3K inhibition
prevents the delayed activation of
MEK-1 , a direct activator of ERK, during oxidative stress
Duca et al., Mol Pharmacol 2005
:
The simultaneous inhibition of PKA and
PI3K , by N- ( 2- ( p-bromocinnamylamino ) ethyl ) -5-isoquinolinesulfonamide ( H89 ) and 2- ( 4-morpholynil ) -8-phenyl-4H-1-bemzopyran-4-one ( LY294002 ), respectively,
blocked MEK1/2 and ERK1/2 phosphorylation, as did lactose, an EBP antagonist
Merino et al., Nephrol Dial Transplant 2008
(Kidney Diseases) :
This inflammatory response was mediated by intracellular signalling
dependent on NF-kappaB, p38 MARK or c-Jun
PI3K but not by
MEK1/2 activation
Choi et al., Stem Cells Dev 2008
(MAP Kinase Signaling System) :
Moreover, the pERK1/2 and pAkt upregulation induced by FGF-2 and -4 were completely abolished by treatment with the
MEK1/2 inhibitor, U0126 and the
PI3K inhibitor , LY294002
Yang et al., Eur J Pharmacol 2010
:
These results suggest that plumbagin activates NAD ( P ) H oxidase, Src, and PI3K, and that the activated
PI3K or PDK1 subsequently
stimulate Akt and
Ras-Raf-MEK1/2-ERK1/2 in 3T3-L1 cells
Lasala et al., Am J Physiol Endocrinol Metab 2011
:
Blocking PKA abolished the effect of cAMP on Sox9, Sf1, and Gata4 expression, inhibiting
PI3K/PKB impaired the effect on Sf1 and Gata4, and
reducing MEK1/2 and p38 MAPK activities curtailed Gata4 increase
Chang et al., Gen Comp Endocrinol 2012
:
The specific inhibitors of either MEK1 ( U-0126 and PD-98059 ), JAK ( AG-490 ), JNK ( SP-600125 ), or
PI3K ( LY-294002 and wortmannin ) reduced ET-1 increased levels of SOCS-3 mRNA and respectively
inhibited ET-1 stimulated activities of
MEK1 , JAK, JNK, and PI3K